Athenex, Inc. 附屬公司Athenex Pharma Solutions (APS) 開始銷售即用型預混IV型袋裝Vasopressin注射針劑
August 14, 2018 07:34 ET
|
Athenex, Inc.
紐約州水牛城, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克︰ATNX）是一家致力於研發、發展以及將治療癌症及相關疾病新型療法商業化的全球生物製藥公司。該公司今日宣佈將透過附屬公司APS開始銷售即用型預混IV型袋裝Vasopressin注射針劑。 ...
Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update
August 14, 2018 07:00 ET
|
Athenex, Inc.
Second quarter revenue increased to $11.6 million compared to $4.6 million in the same period last year. Received a strategic investment of $100 million from Perceptive Advisors Primary endpoints...
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags
August 13, 2018 07:29 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex Pharmaceutical Division獲美國食品藥物管理局批准進口氯化鉀注射濃縮液，以應對美國藥物短缺問題
August 09, 2018 18:15 ET
|
Athenex, Inc.
美國紐約州水牛城, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（NASDAQ：ATNX）是一間全球生物製藥公司，致力於癌症治療新療法的發現、開發和產業化。公司今天宣布美國食品藥物管理局（「FDA」）已批准Athenex Pharmaceutical Division（「APD」）進口氯化鉀注射濃縮液（2...
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
August 09, 2018 09:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.將於2018年8月14日公佈2018會計年度第二季度財務報告
August 03, 2018 08:48 ET
|
Athenex, Inc.
紐約州水牛城, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athenex,...
Athenex, Inc. to Report Second Quarter Earnings Results on August 14, 2018
August 03, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex公佈兩項關於KX2-391對光化性角化病關鍵療效的臨床第三期試驗
July 27, 2018 09:51 ET
|
Athenex, Inc.
美國紐約州水牛城, July 27, 2018 (GLOBE NEWSWIRE) -- 致力於開發、研製和商用癌症及相關症狀新型療法的全球製藥企業Athenex,...
Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
July 26, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣布Axis Therapeutics與香港理工大學簽訂諒解備忘錄，成立癌症免疫療法聯合研究中心
July 18, 2018 12:10 ET
|
Athenex, Inc.
美國紐約州水牛城, July 18, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.（NASDAQ:ATNX）是一間致力開發、研製和商業化癌症和相關疾病新療法的全球生物製藥公司，該公司今天宣布 Axis Therapeutics...